Secretome, Native EVs, or Engineered EVs: What's the Best Cell-Free Cell Therapy?
Wednesday, May 29, 2024 01:00 PM - 02:00 PM
Room 217-219
Clinic & Therapeutic Development
Roundtable
Organized by: ISCT Exosomes Committee
Moderator
Develop strategies to increase the active components in these products and generate value for investors and regulators.
Key Learning Objectives
1. Mutual understanding of scientists, regulators and investors perspective on the active component(s)
2. Limitations in the translation of secretome and EV products into the clinics
3. Requirements and challenges of potency testing.
Moderator
- Bernd Giebel, PhD, University of Duisburg-Essen, Germany
- Claudia dos Santos, MD, MSc, FRCPC, Institution The Keenan Research Centre for Biomedical Science of St. Michael's Hospital, University of Toronto, Canada
- Ornella Parolini, PhD, Università Cattolica del Sacro Cuore, Italy
- Owen Davies, PhD, School of Sport Exercise and Health Sciences, Loughborough University, United Kingdom
- Sai Kiang Lim, PhD, Paracrine Therapeutics, Singapore
Develop strategies to increase the active components in these products and generate value for investors and regulators.
Key Learning Objectives
1. Mutual understanding of scientists, regulators and investors perspective on the active component(s)
2. Limitations in the translation of secretome and EV products into the clinics
3. Requirements and challenges of potency testing.
